中国创新药闪耀ASCO，单日11款新药密集获批！T+0交易的港股通创新药ETF(159570)冲击三连阳，盘中大举吸金7700万元！

Group 1: Market Performance - The Hong Kong stock market showed positive performance, with the Hong Kong Stock Connect Innovative Drug ETF (159570) rising nearly 1% during trading, achieving a transaction volume exceeding 1.2 billion CNY [1] - The ETF has seen a net inflow of 77 million CNY during the trading session and over 1.8 billion CNY in the last 60 days, indicating strong investor interest [1] Group 2: New Drug Approvals - On May 29, the National Medical Products Administration approved 11 new drugs, including several first-in-class or domestically produced drugs in oncology and endocrinology, signaling accelerated development in China's innovative drug sector [2] - Seven of the approved drugs are classified as Category 1, involving companies like Heng Rui Medicine and Hai Chuang Pharmaceutical [2] Group 3: ASCO Conference Highlights - The 2025 ASCO annual meeting showcased significant advancements in domestic dual antibodies and ADCs, indicating strong competitiveness in the global market [4] - Key highlights include breakthroughs in difficult-to-treat tumors and the potential of new molecules like IBI363 and ZG006 to redefine treatment standards [4][11] Group 4: Treatment Innovations - Innovative drugs are expected to address unmet needs in pancreatic cancer treatment, with clinical trials showing promising overall response rates (ORR) of 63.9% and 68.8% for TQB2868 and Sufentanil, respectively [8] - In the second-line treatment of small cell lung cancer (SCLC), ZG006 demonstrated superior efficacy compared to Tarlatamab, with a clinical overall response rate of 75% [11] Group 5: Market Outlook - The ETF manager believes the innovative drug market will continue to thrive due to accelerated commercialization of domestic drugs and favorable changes in U.S. tariff policies [16] - Recent significant overseas licensing deals, such as the one between Sanofi and Pfizer for the PD-1/VEGF drug, are expected to enhance the global clinical progress of these drugs [17]